Displaying drugs 601 - 625 of 1511 in total
Ivarmacitinib
Ivarmacitinib (SHR0302) is a selective inhibitor of Janus kinase 1 (JAK1) under investigation for the treatment of various immuno-inflammatory conditions. While ivarmactinib has yet to receive marketing authorization, as of February 2022 clinical trials are ongoing or completed evaluating its use in atopic dermatitis,[L40604,L40619,L40629] ankylosing spondylitis, rheumatoid arthritis, psoriatic arthritis,...
Experimental
Investigational
Cavrotolimod
Investigational
BMN-044
Experimental
Withdrawn
Brogidirsen
Brogidirsen is under investigation in clinical trial NCT05996003 (NS-089/NCNP-02-201 in Boys With Duchenne Muscular Dystrophy (DMD)).
Investigational
MPT-0L055
Investigational
BPR-0L075
Investigational
U-0126
U-0126 is a direct inhibitor of the mitogen-activated protein-kinase kinase family members, MEK-1 and MEK-2.
Investigational
Stamulumab
MYO-029 is a human anti-GDF-8 monoclonal antibody, which is being developed to treat muscle-wasting diseases including muscular dystrophy and age-related sarcopenia.
Investigational
BMX-001 free base
Investigational
TAK-075 Free base
Investigational
BMN-045
Experimental
Withdrawn
M-032
Investigational
ADVM-053
Investigational
MZE001
Investigational
Erbumine
Investigational
ALMB-0168
ALMB-0168 is a humanized connexin 43 (Cx43) monoclonal antibody being investigated for osteosarcoma.
Investigational
MBP-091
MBP-091 is a monoclonal antibody being investigated for the treatment of Marburg virus disease (MVD) caused by infection with Marburg virus (MARV).
Investigational
AP-001
Investigational
EGEN-001
EGEN-001 is a novel non-viral vector consisting of a plasmid DNA encoding the human gene for interleukin 12 (IL-12) and a biocompatible, biodegradable delivery polymer with potential antineoplastic activity.
Investigational
Verzistobart
Verzistobart is under investigation in clinical trial NCT06056895 (Triple Immune Checkpoint Inhibition for Advanced or Metastatic PD-(L)1 Refractory Merkel Cell Carcinoma).
Investigational
Timdarpacept
IMM01 is a recombinant human signal regulatory protein α (SIRPα) IgG 1 fusion protein. IMM01 is under investigation in clinical trial NCT05140811 (A Study of IMM01 Combined With Azacitidine in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndrome).
Investigational
Barzolvolimab
Barzolvolimab is under investigation in clinical trial NCT06455202 (A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria (CSU)).
Investigational
Etigilimab
Etigilimab is under investigation in clinical trial NCT04761198 (A Study of Etigilimab and Nivolumab in Subjects With Locally Advanced or Metastatic Tumors.).
Investigational
BMN-053
Experimental
Withdrawn
Edobacomab
Investigational
Displaying drugs 601 - 625 of 1511 in total